ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GRO Biosciences raises seed funding

by Ryan Cross
October 2, 2017 | APPEARED IN VOLUME 95, ISSUE 39

GRO Biosciences, a Boston-based synthetic biology start-up that spun out of Harvard University geneticist George Church’s lab, has received $2.1 million in seed funding from Digitalis Ventures and Innovation Endeavors. GRO uses genetically recoded bacteria, which incorporate additional amino acids beyond nature’s standard set of 20 molecules, to improve stability, potency, and other properties of therapeutic proteins. CEO Daniel Mandell says GRO is making antibodies and human growth hormone containing the nontraditional amino acid selenocysteine. The resulting diselenide bonds are more stable than the protein’s original disulfide bonds.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment